Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PRESCRIPTION DRUG COVERAGE INCLUSION IN MINIMUM HEALTH INSURANCE

Executive Summary

PRESCRIPTION DRUG COVERAGE INCLUSION IN MINIMUM HEALTH INSURANCE benefits for all individuals is suggested by the Advisory Council on Social Security at a July 26 meeting. The panel took no official votes on the issue, but concurred informally when asked by Chairwoman Deborah Steelman whether members agreed that drug coverage should be included. The council is designing a minimum health benefits package, but has not yet specified how to ensure that all individuals are covered by such a package. The benefits package will include acute hospital services, diagnostic x-ray and lab services, and medically necessary physician and surgical care for outpatients. The panel agreed that all individuals should be eligible for these core benefits and that low-income families would probably need to be subsidized -- however, it has not delineated what role the government should have in either mandating or financing coverage. The council did not address specific features of a drug benefit. The group plans to discuss the scope of coverage as well as deductibles and copayments at a meeting in September. At that time, staffers will also present cost estimates for the drug coverage. The recommended minimum benefits package will be included in the council's January 1991 report to HHS Secretary Sullivan. The Social Security statutes require that the council be convened periodically. A group assembled in the early 1980s and chaired by Otis Bowen developed Medicare reform proposals that formed the basis for the catastrophic coverage plan Bowen advocated when he became HHS secretary. The current panel is chaired by D.C. attorney Deborah Steelman (Epstein Becker & Green), who acted as the top domestic policy advisor in the Bush presidential campaign. From the outset, the present group has had difficulty reaching agreement. Last fall, Steelman presented one proposal for health care reform after unsuccessfully trying to build a consensus with members individually. The panel then decided to undertake a comprehensive examination of the national helath care system. The council also decided to hold public hearings, an approach Steelman disagreed with in June, saying it would duplicate work already done by others. About five hearings will be held. During the group's discussion, Steelman said that drug coverage "must be included in a minimum benefits package" because it is "one of the most cost-effective services." She indicated that her "personal prejudice" is for a broader benefits package that is accompanied by greater individual cost-sharing. However, commission member Lawrence Atkins, PhD, employee benefits policy director for the New York law firm Winthrop, Stimson, Putnam and Roberts, was more cautious about including drug coverage as a core service. "To require prescription drug [coverage] is a major benefit expansion that will be expensive and difficult to administer," he said, referring to the revoked Medicare catastrophic care drug benefit as evidence. Metropolitan Vice-Chairman Philip Briggs disagreed with Atkins, noting that drug coverage is routinely reimbursed by most private insurers and Medicaid plans, and also is much less expensive for those under age 65.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel